Education & Training

 

AGA Education, Practice and Research

Focused Clincial Updates 2006

To receive full CME credit, you are required to complete the evaluation form and self-test for each chapter you complete. Upon completion of the evaluation form and test, a certificate with your name and number of credits you have claimed will be generated. You must print your certificate using the print function in your browser.

The objectives listed below are to be used when evaluating the program. After completing this program, each participant should be able to:

  • Identify how state of the art and emerging research will impact management of digestive conditions.
  • Review diagnostic and treatment options for patients with several digestive diseases.

 

Probiotics and Antibiotics in IBD/IBS

Select one answer for each question. You may change your answers as many times as you need to until you click the "Submit" button located at the bottom of the test.

1. Patients with ulcerative colitis in remission randomized to lactobacillus, Bifidobacterium, or placebo:

Bifidobacterium was superior to both arms in maintenance of remission

lactobacillus was superior to the other two arms in maintenance of remission

Relapse was less frequent with placebo compared to the active probiotics

The risk of relapse was similar across all three groups

2. Regarding Clostridium difficile infection in patients with inflammatory bowel disease:

The incidence of C. difficile increased for Crohn's disease and ulcerative colitis over the seven year period of 1998 to 2004

C. difficile was seen in greater frequency in ulcerative colitis compared to Crohn's

C. difficile was more frequent in Crohn's and ulcerative colitis compared to non-IBD admissions

All are correct

3. Treatment of Traveler's diarrhea:

Rifaximin was no better than loperamide alone in improvement of diarrhea

Loperamide was superior to rifaximin alone in improvement of diarrhea

Rifaximin plus loperamide provided the most rapid initial symptomatic improvement and long-term results comparied to either alone

None of the above are correct

4. Rectally administered E. coli Nissle 1917 for ulcerative colitis:

Is more poorl tolerated than placebo

Shows a dose-dependent response with rectally administered bacteria compared to placebo

Shows no difference compared to placebo in overall remission rate

Shows improvement in endoscopic remission not clinical remission